| scholarly article | Q13442814 |
| P50 | author | Ralph L Sacco | Q69142484 |
| Bruce Levin | Q104884393 | ||
| Jay P. Mohr | Q124792359 | ||
| P2093 | author name string | Robert R Sciacca | |
| Steven R Levine | |||
| Robin L Brey | |||
| Barbara C Tilley | |||
| A Murphy | |||
| Douglas A Triplett | |||
| Candi Rhine | |||
| J L P Thompson | |||
| Teresa M Costigan | |||
| Yimeng Lu | |||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| patient | Q181600 | ||
| P304 | page(s) | 576-84 | |
| P577 | publication date | 2004-02-04 | |
| P1433 | published in | The Journal of the American Medical Association | Q1470970 |
| P1476 | title | Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke | |
| P478 | volume | 291 |
| Q95359426 | Q95359426 |
| Q90446471 | A challenging case of neuropsychiatric systematic lupus erythematosus with recurrent antiphospholipid- related stroke: A case report and literature review |
| Q81201365 | A protocol for determination of anticardiolipin antibodies by ELISA |
| Q28174751 | A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS) |
| Q37790448 | A review of hereditary and acquired coagulation disorders in the aetiology of ischaemic stroke |
| Q36461116 | Accelerated atherosclerosis, arterial thromboembolism, and preventive strategies in systemic lupus erythematosus |
| Q51846266 | Acquired Thrombophilia. |
| Q36642014 | Amino terminal pro-B-type natriuretic peptide, secondary stroke prevention, and choice of antithrombotic therapy |
| Q42283118 | Anti-Phosphatidylserine-Prothrombin Antibodies are Associated with Outcome in a TIA Cohort |
| Q35934717 | Antiphospholipid (Hughes) syndrome |
| Q30355477 | Antiphospholipid Antibodies and Recurrent Thrombotic Events: Persistence and Portfolio. |
| Q48443751 | Antiphospholipid antibodies correlate with stroke severity and outcome in patients with antiphospholipid syndrome |
| Q28192380 | Antiphospholipid antibodies in young adults with stroke |
| Q83162687 | Antiphospholipid antibodies predict imminent vascular events independently from other risk factors in a prospective cohort |
| Q36802556 | Antiphospholipid antibodies, brain infarcts, and cognitive and motor decline in aging (ABICMA): design of a community-based, longitudinal, clinical-pathological study |
| Q55891386 | Antiphospholipid syndrome |
| Q64046338 | Antiphospholipid syndrome |
| Q34307502 | Antiphospholipid syndrome and the brain in pediatric and adult patients |
| Q38596401 | Antiphospholipid syndrome presenting as cerebral venous sinus thrombosis: a case series and a review |
| Q37842673 | Antiphospholipid syndrome: laboratory detection, mechanisms of action and treatment. |
| Q35775322 | Antiphospholipid syndrome: multiple mechanisms |
| Q83286182 | Antiphospholipid syndrome: unusual clinical presentations |
| Q37269861 | Antithrombotic agents for stroke prevention |
| Q35752603 | Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines |
| Q53093982 | Antithrombotic treatment for stroke associated with antiphospholipid antibodies. |
| Q37319989 | Atherosclerosis in autoimmune rheumatic diseases-mechanisms and clinical findings |
| Q28196276 | Cerebrovascular disease associated with antiphospholipid antibodies: more questions than answers |
| Q53552867 | Classical and additional antiphospholipid antibodies in blood samples of ischemic stroke patients and healthy controls. |
| Q37076800 | Controversies in the antiphospholipid syndrome: can we ever stop warfarin? |
| Q38150761 | Cryptogenic stroke: how to define it? How to treat it? |
| Q37642830 | Current management of antiphospholipid syndrome-related thrombosis |
| Q38818425 | Current status and future prospects for the treatment of antiphospholipid syndrome |
| Q42432752 | Decoding cryptogenic cardioembolism |
| Q47982275 | Diagnosis and management of the antiphospholipid syndrome |
| Q41222650 | Efficacy and safety of rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome: Rationale and design of the Trial on Rivaroxaban in AntiPhospholipid Syndrome (TRAPS) trial |
| Q37350213 | Genetics of ischemic stroke: inheritance of a sporadic disorder |
| Q22306331 | Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association |
| Q34821893 | Guidelines for the treatment of antiphospholipid syndrome |
| Q37982121 | Guidelines on the investigation and management of antiphospholipid syndrome |
| Q37274431 | Hematological diseases and stroke |
| Q33374874 | Hughes Syndrome: the antiphospholipid syndrome--a clinical overview |
| Q37101366 | Hughes syndrome (the antiphospholipid syndrome): 25 years old. |
| Q31101744 | Hughes syndrome and epilepsy: when to test for antiphospholipid antibodies? |
| Q36254845 | Hypercoagulable states and stroke: a selective review. |
| Q38856073 | IgG/IgM antiphospholipid antibodies present in the classification criteria for the antiphospholipid syndrome: a critical review of their association with thrombosis |
| Q33705494 | Immunologically mediated dementias |
| Q37738699 | Intensity of warfarin coagulation in the antiphospholipid syndrome |
| Q36458164 | Laboratory diagnosis and management challenges in the antiphospholipid syndrome |
| Q40421733 | Longitudinal myelitis, aseptic meningitis, and conus medullaris infarction as presenting manifestations of pediatric systemic lupus erythematosus |
| Q26774815 | Management of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future Perspectives |
| Q98181529 | Management of anticoagulant-refractory thrombotic antiphospholipid syndrome |
| Q57656275 | Management of antiphospholipid syndrome |
| Q64910478 | Management of thrombotic and obstetric antiphospholipid syndrome: a systematic literature review informing the EULAR recommendations for the management of antiphospholipid syndrome in adults. |
| Q37408830 | Molecular biomarkers in stroke diagnosis and prognosis |
| Q35979170 | Neonatal stroke associated with de novo antiphospholipid antibody and homozygous 1298C/C methylenetetrahydrofolate reductase mutation |
| Q80335294 | Neurologic manifestations of the antiphospholipid syndrome |
| Q37154879 | Neurologic manifestations of the antiphospholipid syndrome: integrating molecular and clinical lessons |
| Q37404485 | New approaches for managing antiphospholipid syndrome |
| Q37168035 | New developments in lupus-associated antiphospholipid syndrome |
| Q28174743 | Oral anticoagulation for the antiphospholipid antibody syndrome: can we now say less is more? |
| Q51405063 | Osteonecrosis in patients after severe acute respiratory syndrome (SARS): possible role of anticardiolipin antibodies. |
| Q39038954 | PPARγ activation rescues mitochondrial function from inhibition of complex I and loss of PINK1. |
| Q37385436 | Patent foramen ovale, cardiac valve thickening, and antiphospholipid antibodies as risk factors for subsequent vascular events: the PICSS-APASS study |
| Q39198671 | Pathogenesis and management of antiphospholipid syndrome |
| Q51821388 | Pathogenesis and management of antiphospholipid syndrome. |
| Q40221778 | Patients with antiphosholipid syndrome and thrombotic recurrences: A real world observation (the Piedmont cohort study). |
| Q41100232 | Pediatric antiphospholipid syndrome |
| Q37832976 | Practical issues with vitamin K antagonists: elevated INRs, low time-in-therapeutic range, and warfarin failure |
| Q49299419 | Practice Current: What is your diagnostic evaluation of cryptogenic stroke? |
| Q38794847 | Prevention of Recurrent Thrombosis in Antiphospholipid Syndrome: Different from the General Population? |
| Q38612651 | Prevention of Stroke in Rheumatoid Arthritis |
| Q22306369 | Primary prevention of ischemic stroke |
| Q28181645 | Randomized clinical stroke trials in 2004 |
| Q91955549 | Rationale for ischemic conditioning to prevent stroke in patients with intracranial arterial stenosis |
| Q38070816 | Recent advances in the management of transient ischaemic attack: a clinical review |
| Q41830826 | Recurrent stent thrombosis in a patient with antiphospholipid syndrome and dual anti-platelet therapy non-responsiveness. |
| Q89777587 | Recurrent thrombosis in patients with antiphospholipid antibodies and arterial thrombosis on antithrombotic therapy |
| Q34943841 | Relation of antiphospholipid antibodies to postmortem brain infarcts in older people |
| Q34472618 | Risk factors for ischemic stroke and transient ischemic attack in patients under age 50 |
| Q53096573 | Role of anticardiolipin antibodies in the pathogenesis of prosthetic valve thrombosis: An observational study. |
| Q34573328 | Role of investigating thrombophilic disorders in young stroke. |
| Q37775992 | Screening for coagulation disorders in patients with ischemic stroke |
| Q28167729 | Secondary prevention of stroke: a practical guide to drug treatment |
| Q35198604 | Sex differences in antiplatelet response in ischemic stroke |
| Q27022768 | Sex differences in stroke: the contribution of coagulation |
| Q38844621 | Stroke in systemic lupus erythematosus and antiphospholipid syndrome: risk factors, clinical manifestations, neuroimaging, and treatment |
| Q42646992 | Subsequent Thrombotic Outcomes in Patients with Ischemic Stroke with Antiphospholipid Antibody Positivity |
| Q55933861 | Systemic lupus erythematosus |
| Q36928593 | The antiphospholipid syndrome: still an enigma |
| Q36395274 | The antiphospholipid syndrome: what are we really measuring? How do we measure it? And how do we treat it? |
| Q38768065 | The aspirin story - from willow to wonder drug. |
| Q48081474 | The chequered history of the antiphospholipid syndrome. |
| Q37959884 | The management of stroke in antiphospholipid syndrome |
| Q50248970 | The wound/burn guidelines - 4: Guidelines for the management of skin ulcers associated with connective tissue disease/vasculitis. |
| Q37721614 | Towards evidence-based treatment of thrombotic antiphospholipid syndrome |
| Q35621012 | Treatment of Thrombotic Antiphospholipid Syndrome: The Rationale of Current Management-An Insight into Future Approaches |
| Q35648075 | Treatment of risk factors to prevent stroke |
| Q35940099 | Treatment of the antiphospholipid antibody syndrome |
| Q35308972 | Treatment of the antiphospholipid syndrome |
| Q43078028 | Update of secondary stroke prevention |
| Q36131773 | Update on stroke prevention |
| Q64914934 | Very late stent thrombosis after drug-eluting stent implantation in a patient with antiphospholipid syndrome. |
| Q84600032 | [Antiphospholipid syndrome treatment, to whom, when and how long?] |
| Q81153272 | [Cerebral infarction of arterial origin and haematological causation: the Lausanne experience and a review of the literature] |
Search more.